BioSig Subsidiary ViralClear Submits Application for Vicromax™ Through FDA’s Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials April 21, 2020
Mayo Clinic Preparing to Commence Phase II FDA Clinical Trial for the Treatment of COVID-19 with Vicromax™ April 16, 2020
Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv April 9, 2020
BioSig to Host Telebriefing on Development Updates Regarding Vicromax(tm), a Novel Broad-Spectrum Anti-Viral Candidate That May Treat COVID-19 April 3, 2020
Jerome Zeldis, M.D., Ph.D, Appointed as Executive Chair of ViralClear Pharmaceuticals, Inc. March 31, 2020
BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture March 25, 2020
Florida Cardiologist Zachariah P. Zachariah, M.D. Joins BioSig Technologies, Inc. Advisory Board March 10, 2020
BioSig to Webcast its Presentation at the Cowen and Company’s 40th Annual Health Care Conference March 3, 2020
